GLOBAL HEALTH VOYAGER INC

CIK:0000318622|SEC Filings

Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended		169 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
Consolidated Statements Of Operations
REVENUES					$ 385,997
COSTS AND EXPENSES
General and administrative	90,362	99,475	131,919	207,943	7,764,771
Depreciation and amortization					132,077
Impairment of film costs					156,445
Impairment of related party receivables					35,383
Inventory write-down					24,820
Loss on litigation settlement			10,000		110,000
TOTAL COSTS AND EXPENSES	90,362	99,475	141,919	207,943	8,223,496
LOSS FROM OPERATIONS	(90,362)	(99,475)	(141,919)	(207,943)	(7,837,499)
OTHER INCOME (EXPENSES)
Other income				630	26,137
Other expense					(536,895)
Interest expense	(82,710)	(58,509)	(176,607)	(116,446)	(1,536,602)
Interest expense, related party	(1,044)	(1,294)	(2,082)	(2,613)	(545,896)
Loan fees					(616,000)
Debt forgiven					290,595
Legal fees forgiven					12,296
Provision for common stock subscription receivable					(91,552)
TOTAL OTHER EXPENSE, NET	(83,754)	(59,803)	(178,689)	(118,429)	(2,997,917)
LOSS BEFORE PROVISION FOR INCOME TAXES AND NONCONTROLLING INTEREST	(174,116)	(159,278)	(320,608)	(326,372)	(10,835,416)
PROVISION FOR INCOME TAXES					16,800
LOSS BEFORE NON-CONTROLLING INTEREST	(174,116)	(159,278)	(320,608)	(326,372)	(10,852,216)
LESS LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST					33,000
NET LOSS ATTRIBUTABLE TO GLOBAL HEALTH VOYAGER, INC. AND SUBSIDIARIES	$ (174,116)	$ (159,278)	$ (320,608)	$ (326,372)	$ (10,819,216)
NET LOSS PER SHARE
BASIC AND DILUTED	$ 0.00	$ 0.00	$ 0.00	$ (0.01)
WEIGHTED AVERAGE SHARES OUTSTANDING
BASIC AND DILUTED	93,424,563	44,862,320	84,569,007	41,957,186

Consolidated Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended		169 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss before non-controlling interest	$ (320,608)	$ (326,372)	$ (10,852,216)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for prepayment			73,732
Gain on conversion of notes		(630)	(630)
Amortized interest on warrants	2,685	2,686	11,072
Depreciation and amortization			132,077
Impairment loss			336,773
Inventory write-down			24,820
Impairment of related party receivables			35,383
Operating expenses paid by reducing note receivable			10,000
Stock issued for services		22,988	1,441,737
Deferred compensation			10,417
Stock issued for loan fees			423,000
Stock options issued for services			60,370
Stock issued for litigation settlements	10,000		10,000
Debts forgiven			(302,891)
Provision for common stock subscription receivable			89,468
Amount attributable to non-controlling interest			33,000
Interest expense on beneficial conversion of debt	51,997		883,025
Changes in assets and liabilities:
Interest receivable			(19,986)
Inventory			(24,820)
Prepaid Expenses			(73,732)
Other assets			(24,000)
Accrued litigation settlements			100,000
Accounts payable and accrued expenses	102,445	101,295	2,179,426
Accrued expenses, related parties	103,148	75,000	1,609,129
Net cash used in operating activities	(50,333)	(125,032)	(3,834,846)
CASH FLOWS FROM INVESTING ACTIVITIES:
Notes receivable from officer			(45,048)
Collection of notes receivable from officer			35,048
Notes receivable, related parties			(50,000)
Collection of notes receivable, related parties			50,000
Investment in property and equipment			(18,879)
Investment in film costs			(133,005)
Investment in web site development costs			(292,968)
Net cash used in investing activities			(454,852)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock			1,254,154
Payment of offering costs			(66,450)
Proceeds from notes payable		94,100	1,716,572
Proceeds from notes payable, related party	450	2,000	688,945
Payments of notes payable	(19,100)	(19,135)	(299,351)
Payments of notes payable, related party		(3,233)	(431,955)
Proceeds from issuance of convertible notes	69,000	52,501	1,427,800
Net cash provided by financing activities	50,350	126,233	4,289,715
NET INCREASE (DECREASE) IN CASH AND EQUIVALENTS	17	1,201	17
CASH AND EQUIVALENTS, Beginning of period		799
CASH AND EQUIVALENTS, End of period	17	2,000	17
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the period for: Interest paid	900	1,962	24,284
Cash paid during the period for: Income taxes paid			4,000
NONCASH FINANCING ACTIVITIES:
Conversion of debts and accrued interest	18,650	66,735	620,881
Stock issued for loan fees			$ 423,000

Consolidated Balance Sheets (Unaudited) (USD $)	Jun. 30, 2013	Dec. 31, 2012
ASSETS
Cash and equivalents	$ 17
TOTAL ASSETS	17
LIABILITIES AND STOCKHOLDERS' DEFICIT
Accounts payable	587,870	590,221
Accrued liabilities	1,546,379	1,442,126
Accrued liabilities, related parties	1,252,342	1,149,195
Notes payable	1,231,470	1,250,570
Notes payable, related party	34,798	34,348
Convertible notes payable, net of unamortized beneficial conversion feature	926,722	880,287
Accrued litigation settlements	113,178	113,178
TOTAL CURRENT LIABILITIES	5,692,759	5,459,925
Convertible notes payable	359,962	357,277
TOTAL LIABILITES	6,052,721	5,817,202
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
Preferred stock, $0.001 par value, 5,000,000 shares authorized; 0 shares issued and outstanding
Common stock; $0.001 par value; 1,000,000,000 shares authorized; 93,424,564 and 52,924,564 shares issued and outstanding at June 30, 2013 and December 31, 2012	93,424	52,924
Additional paid-in capital	4,673,087	4,628,482
Deficit accumulated during the development stage	(10,819,215)	(10,498,608)
TOTAL STOCKHOLDERS' DEFICIT	(6,052,704)	(5,817,202)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 17